title: TRAIL expression levels in human hepatocellular carcinoma have implications for tumor growth, recurrence and survival.
abstract: The proapoptotic molecule TNF-related apoptosis-inducing ligand (TRAIL) has earned attention because of its ability to induce apoptosis in liver cancer cells without damaging normal liver cells. It may play an important role in preventing the development and outgrowth of hepatocellular carcinoma (HCC). TRAIL expression was investigated in a large series of human HCCs. We analyzed liver tissue from 108 patients undergoing partial liver resection (PLR) or liver transplantation (LT) because of either HCC or other indications. TRAIL expression was correlated with the cause of liver disease, demographic and clinical variables and pathologic properties. Our analysis found that in 66% of HCCs TRAIL expression was significantly lower than in the surrounding non-cancerous liver tissue (p≤0.012). Separation by cause of disease showed that HCC TRAIL mRNA expression was lower in almost all groups than in non-cancerous tissue but most significantly lower in NASH-associated liver tumors. Interestingly, low HCC TRAIL expression was found to correlate with tumor size (p≤0.007) and stage, as well as with tumor recurrence after resection and poor survival rates. The results of this study suggest that low TRAIL mRNA levels may be both a dominant feature in HCC development and growth and a predictor of tumor recurrence and poorer survival rates.
authors.affiliation: Deparment of General, Visceral, and Transplantation Surgery, University Hospital Essen, Germany; Department of Gastroenterology and Hepatology, University Hospital Essen, Germany.
authors.forename: Katja
authors.initials: K
authors.lastname: Piras-Straub
authors.forename: Khaleda
authors.initials: K
authors.lastname: Khairzada
authors.forename: Martin
authors.initials: M
authors.lastname: Trippler
authors.forename: Hideo A
authors.initials: HA
authors.lastname: Baba
authors.forename: Gernot M
authors.initials: GM
authors.lastname: Kaiser
authors.forename: Andreas
authors.initials: A
authors.lastname: Paul
authors.forename: Ali
authors.initials: A
authors.lastname: Canbay
authors.forename: Frank
authors.initials: F
authors.lastname: Weber
authors.forename: Guido
authors.initials: G
authors.lastname: Gerken
authors.forename: Kerstin
authors.initials: K
authors.lastname: Herzer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D015870:Gene Expression; D006801:Humans; D053208:Kaplan-Meier Estimate; D008099:Liver / Q000378:metabolism; D008113:Liver Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism*; D011379:Prognosis; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000235:genetics / Q000378:metabolism*; D047368:Tumor Burden; D055815:Young Adult
chemical_list: D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human
keywords: HCC recurrence; TRAIL; hepatocellular carcinoma; liver resection; liver transplantation